amp semaglutide FDA Warns on Certain Forms of Compounded Semaglutide: Benefits, Side Effects, Before-and-After

Unlike existing approved therapies, it simultaneously targets GLP-1, GIP, and glucagon receptors, a mechanism that early clinical data suggest may produce substantial metabolic effects

The treatment, an investigational once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, met its primary endpoints in both trials, delivering substantial weight loss across high-risk populations including adults with type 2 diabetes and those with severe obesity and established cardiovascular disease

Unlike the Wegovy pill, which must be taken first thing in the morning on an empty stomach, this medication can be taken at any point during the day without regard to meals

CT-388 is an orally or injectably administered dual GLP-1R and GIPR agonist that is in the early stages of development